OBJECTIVE: To determine whether a functional single-nucleotide polymorphism in the gene encoding Fcgamma receptor type IIIA (FcgammaRIIIA) correlates with the response to treatment with tumor necrosis factor alpha inhibitors in rheumatoid arthritis (RA). METHODS: The study population comprised 282 Swedish patients with RA in whom the therapeutic efficacy of conventional disease-modifying antirheumatic drugs had been insufficient. Infliximab or etanercept treatment was initiated, and patients were evaluated after 3 months, using the American College of Rheumatology 20% improvement criteria (ACR20), the ACR50, and the ACR70 or the European League Against Rheumatism (EULAR) criteria. The chi-square test was used to compare response rates across FcgammaRIIIA genotypes. RESULTS: No differences in genotype distribution were observed among nonresponders compared with ACR20 responders (P = 0.80), ACR50 responders (P = 0.56), or ACR70 responders (P = 0.91). Similar results were observed when analyzing infliximab and etanercept separately or when using the EULAR response criteria. CONCLUSION: Unlike the findings of a previous study, the results of the current study suggest that the 158V/F polymorphism of FcgammaRIIIA is very unlikely to influence the clinical efficacy of infliximab or etanercept in patients with RA.
OBJECTIVE: To determine whether a functional single-nucleotide polymorphism in the gene encoding Fcgamma receptor type IIIA (FcgammaRIIIA) correlates with the response to treatment with tumor necrosis factor alpha inhibitors in rheumatoid arthritis (RA). METHODS: The study population comprised 282 Swedish patients with RA in whom the therapeutic efficacy of conventional disease-modifying antirheumatic drugs had been insufficient. Infliximab or etanercept treatment was initiated, and patients were evaluated after 3 months, using the American College of Rheumatology 20% improvement criteria (ACR20), the ACR50, and the ACR70 or the European League Against Rheumatism (EULAR) criteria. The chi-square test was used to compare response rates across FcgammaRIIIA genotypes. RESULTS: No differences in genotype distribution were observed among nonresponders compared with ACR20 responders (P = 0.80), ACR50 responders (P = 0.56), or ACR70 responders (P = 0.91). Similar results were observed when analyzing infliximab and etanercept separately or when using the EULAR response criteria. CONCLUSION: Unlike the findings of a previous study, the results of the current study suggest that the 158V/F polymorphism of FcgammaRIIIA is very unlikely to influence the clinical efficacy of infliximab or etanercept in patients with RA.
Authors: Paula I Burgos; Maria I Danila; James M Kelley; Laura B Hughes; S Louis Bridges Journal: Ther Adv Musculoskelet Dis Date: 2009-04 Impact factor: 5.346
Authors: Aparna Chhibber; Deanna L Kroetz; Kelan G Tantisira; Michael McGeachie; Cheng Cheng; Robert Plenge; Eli Stahl; Wolfgang Sadee; Marylyn D Ritchie; Sarah A Pendergrass Journal: Pharmacogenomics Date: 2014-12 Impact factor: 2.533
Authors: E Mendrinou; A Patsatsi; E Zafiriou; D Papadopoulou; L Aggelou; C Sarri; Z Mamuris; A Kyriakou; D Sotiriadis; A Roussaki-Schulze; T Sarafidou; Y Vasilopoulos Journal: Pharmacogenomics J Date: 2016-04-05 Impact factor: 3.550
Authors: Marieke J H Coenen; Christian Enevold; Pilar Barrera; Mascha M V A P Schijvenaars; Erik J M Toonen; Hans Scheffer; Leonid Padyukov; Alf Kastbom; Lars Klareskog; Anne Barton; Wietske Kievit; Maarten J Rood; Tim L Jansen; Dorine Swinkels; Piet L C M van Riel; Barbara Franke; Klaus Bendtzen; Timothy R D J Radstake Journal: PLoS One Date: 2010-12-15 Impact factor: 3.240
Authors: Alf Kastbom; Lars Cöster; Lisbeth Arlestig; Aikaterini Chatzidionysiou; Ronald F van Vollenhoven; Leonid Padyukov; Solbritt Rantapää-Dahlqvist; Saedis Saevarsdottir Journal: BMJ Open Date: 2012-09-22 Impact factor: 2.692